Nuvilex, Inc. Phase III Clinical Trials in Strong Hands With Dr. Gerald Crabtree
01 avr. 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwire - Apr 1, 2013) - Nuvilex, Inc. (OTCQB: NVLX) CEO, Dr. Robert Ryan knew exactly what he was doing two years ago when he announced Dr. Gerald Crabtree would be joining his...
Potential Future Sales of Nuvilex, Inc. Cancer Treatments Make Investment in Cell-in-a-Box Worth It
26 mars 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwire - Mar 26, 2013) - Nuvilex, Inc. (OTCQB: NVLX) is a small biotechnology company out of Silver Spring, Maryland, but its future might be anything but small. As the company...
Timing Is Right for Big Pharma to Add Nuvilex, Inc. Technology to Its Pipeline
21 mars 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwire - Mar 21, 2013) - Nuvilex, Inc. (OTCQB: NVLX) has close to $30-million invested in its "Cell-in-a-Box" technology, and as the company gets closer to the start of its...
Nuvilex, Inc. Diabetes Studies Could Eliminate Need for Daily Insulin Requirements
18 mars 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwire - Mar 18, 2013) - When investors look into biotechnology and pharmaceutical companies as an investment opportunity, three areas of research stand out as the most favorable...
Mesoblast Completes A$170m Private Placement
13 mars 2013 23h08 HE
|
Mesoblast
MELBOURNE, Australia, March 13, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has completed a private placement of its...
Hanover to Monetize Underutilized Patents by Converting Them Into Royalty Generating Assets
06 févr. 2013 06h00 HE
|
Hanover Portfolio Acquisitions
LOS ANGELES, CA--(Marketwire - Feb 6, 2013) - Hanover Portfolio Acquisitions (OTCQB: HVPA), an intellectual property investment and monetization firm, announced today that it is actively in talks...
Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Patients With Active Rheumatoid Arthritis
29 janv. 2013 20h25 HE
|
Mesoblast
Key Points:
Mesoblast receives clearance from United States Food and Drug Administration (FDA) to begin Phase 2 trial of proprietary allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells...
Patients' Own Skin Cells Are Transformed Into Heart Cells to Create "Disease in a Dish"
27 janv. 2013 13h13 HE
|
Sanford-Burnham Medical Research Institute
LA JOLLA, Calif., Jan. 27, 2013 (GLOBE NEWSWIRE) -- Most patients with an inherited heart condition known as arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) don't know they have a...
Mesoblast's NeoFuse Stem Cell Product Shows Positive Results in Phase 2 Lumbar Spinal Fusion Trial
10 janv. 2013 22h35 HE
|
Mesoblast
Key points:
Phase 2 trial results using Mesoblast's allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) demonstrated rates of fusion success that were comparable to the gold...
IP Resources Arranges Licensing Deal for New Stem Cell Skin Care Product on Forbes List of Top 10 Fashion and Beauty Startups for 2012
10 janv. 2013 06h00 HE
|
IP Resources International
LOS ANGELES, CA--(Marketwire - Jan 10, 2013) - Hanover Portfolio Acquisitions (OTCQB: HVPA) and its wholly owned subsidiary IP Resources International, an intellectual property licensing and...